drugset / Trial / NCT03977805

Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

NCT03977805

Phase 1 Completed 6 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

This study is a single-center, open-label, single-dose design. It is planning to enroll six Chinese healthy adult male subjects. The metabolism and disposition of Herombopag, will be studied in these subjects after a single oral administration of a solution dose of \[14C\] Herombopag (5 mg, 100 uCi).

Timeline

Start
2019-05-25
Primary completion
2019-06-13
Completion
2019-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Hetrombopag Small molecule 5 mg Oral

Indications

No indication recorded.